Compare HAFN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFN | ERAS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2020 | 2021 |
| Metric | HAFN | ERAS |
|---|---|---|
| Price | $8.83 | $13.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $11.50 | ★ $25.10 |
| AVG Volume (30 Days) | 2.0M | ★ 5.1M |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | ★ 12.37% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.17 | $2.81 |
| 52 Week High | $11.12 | $24.28 |
| Indicator | HAFN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 42.80 |
| Support Level | $8.54 | $13.18 |
| Resistance Level | $9.06 | $15.71 |
| Average True Range (ATR) | 0.36 | 1.31 |
| MACD | -0.12 | -0.13 |
| Stochastic Oscillator | 5.97 | 14.12 |
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.